Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study

Am J Hematol. 2021 Jul 1;96(7):E265-E268. doi: 10.1002/ajh.26195. Epub 2021 May 1.

Authors

Omer Jamy¹, Richard Godby², Rehan Sarmad¹, Luciano J Costa¹

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
² Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

PMID: 33864684
DOI: 10.1002/ajh.26195

No abstract available

Publication types

Letter

MeSH terms

Aged
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology
Male
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Survival Analysis
United States / epidemiology

Substances

Protein Kinase Inhibitors
Protein-Tyrosine Kinases